Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

The Lancet Oncology

Volumn 12, Issue 8, 2011, Pages 815-824

  Laurie, Scott A ^a   Ho, Alan L ^b   Fury, Matthew G ^b   Sherman, Eric ^b   Pfister, David G ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ADENOID CYSTIC CARCINOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SALIVARY GLAND; SYSTEMATIC REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOID CYSTIC; CLINICAL TRIALS AS TOPIC; HUMANS; RECURRENCE; SALIVARY GLAND NEOPLASMS;

EID: 79960892453     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70245-X     Document Type: Review

References (57)

1. Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 1996, 83:1750-1754.
2. Anderson JN, Beenken SW, Crowe R, et al. Prognostic factors in minor salivary gland cancer. Head Neck 1995, 17:480-486.
3. Spiro RH Management of malignant tumors of the salivary glands. Oncology (Williston Park) 1998, 12:671-680.
4. Spiro RH, Huvos AG Stage means more than grade in adenoid cystic carcinoma. Am J Surg 1992, 164:623-628.
5. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004, 26:681-692.
6. van der Wal JE, Becking AG, Snow GB, van der Waal I Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 2002, 24:779-783.
7. Spiro RH Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997, 174:495-498.
8. Meert AP, Berghmans T, Branle F, et al. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res 1999, 19:4379-4390.
9. Gedlicka C, Schull B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs 2002, 13:491-495.
10. de Haan LD, De Mulder PH, Vermorken JB, Schornagel JH, Vermey A, Verweij J Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992, 14:273-277.
11. Kaplan MJ, Johns ME, Cantrell RW Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986, 95:165-170.
12. Tannock IF, Sutherland DJ Chemotherapy for adenocystic carcinoma. Cancer 1980, 46:452-454.
13. Rentschler R, Burgess MA, Byers R Chemotherapy of malignant major salivary gland neoplasms: a 25-year review of M D Anderson Hospital experience. Cancer 1977, 40:619-624.
14. Sessions RB, Lehane DE, Smith RJ, Bryan RN, Suen JY Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol 1982, 108:221-224.
15. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007, 25:3978-3984.
16. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001, 91:541-547.
17. Argiris A, Goldwasser MA, Burtness B, et al. Phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 2006, 24. abstr 5573.
18. Dimery IW, Legha SS, Shirinian M, Hong WK Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990, 8:1056-1062.
19. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006, 28:197-204.
20. Glisson B, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M Phase II trial of gefitinib in patients with incurable salivary gland cancer. Proc Am Soc Clin Oncol 2005, 23. abstr 5532.
21. Guigay JM, Bidault F, Temam S, Janot F, Raymond E, Faivre S Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. Proc Am Soc Clin Oncol 2007, 25. abstr 6086.
22. Hill ME, Constenla DO, A'Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997, 33:275-278.
23. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005, 23:585-590.
24. Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in advanced salivary gland cancers: a trial of the NCIC Clinical Trials Group. Cancer 2010, 116:362-368.
25. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck 2005, 27:1022-1027.
26. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009, 45:574-578.
27. Mattox DE, Von Hoff DD, Balcerzak SP Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest New Drugs 1990, 8:105-107.
28. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007, 43:33-36.
29. Ross PJ, Teoh EM, A'Hern RP, et al. Epirubicin, cisplatin and protracted venous infusion 5-fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol) 2009, 21:311-314.
30. Slevin NJ, Mais KL, Bruce I Imatinib with cisplatin in recurrent and/or metastatic adenoidcystic carcinoma-preliminary results of a phase II study of 18 patients with response assessed by morphological and functional imaging. Eur J Cancer Supplements 2005, 3:292-293.
31. Triozzi PL, Brantley A, Fisher S, Cole TB, Crocker I, Huang AT 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 1987, 59:887-890.
32. van Herpen CM, Locati LD, Buter J, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008, 44:2542-2545.
33. Venook AP, Tseng A, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987, 5:951-955.
34. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993, 4:785-788.
35. Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996, 7:867-869.
36. Schramm VL, Srodes C, Myers EN Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981, 107:739-741.
37. Posner MR, Ervin TJ, Weichselbaum RR, Fabian RL, Miller D Chemotherapy of advanced salivary gland neoplasms. Cancer 1982, 50:2261-2264.
38. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM, Miller D Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987, 60:2869-2872.
39. Belani CP, Eisenberger MA, Gray WC Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 1988, 16:197-202.
40. Tsukuda M, Kokatsu T, Ito K, Mochimatsu I, Kubota A, Sawaki S Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol 1993, 119:756-758.
41. Creagan ET, Woods JE, Rubin J, Schaid DJ Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988, 62:2313-2319.
42. Airoldi M, Pedani F, Brando V, Gabriele P, Giordano C Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 1989, 75:252-256.
43. Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000, 20:3781-3783.
44. Ochel HJ, Gademann G, Rocken C, Wordehoff H Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res 2005, 25:3659-3664.
45. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: a phase II trial of 22 patients. Ann Oncol 1996, 7:640-642.
46. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients. Cancer 1991, 68:1874-1877.
47. Holst VA, Marshall CE, Moskaluk CA, Frierson HF KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999, 12:956-960.
48. (accessed Sept 6, 2007). http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=47&sessionID=2215.
49. Locati LD, Quattrone P, Tomborini E Investigation of molecular targets for therapy in salivary gland carcinoma. Eur J Cancer Supplements 2001, 37:103-104.
50. Licitra L, Locati LD, Potepan P, et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional phase II study. Proc Am Soc Clin Oncol 2006, 24. abstr 5547.
51. Mariani L, Marubini E Content and quality of currently published phase II cancer trials. J Clin Oncol 2000, 18:429-436.
52. Vila L, Liu H, Al-Quran SZ, Coco DP, Dong HJ, Liu C Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 2009, 22:1296-1302.
53. Trendell-Smith NJ, Peston D, Shousha S Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins. Histopathology 1999, 35:241-248.
54. Dori S, Trougouboff P, David R, Buchner A Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol 2000, 36:450-453.
55. Dahse R, Driemel O, Schwarz S, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009, 100:623-625.
56. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004, 10:944-946.
57. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2003, 39:724-727.